Simplify the manufacturing process, improve scalability and offer new opportunities for oral biologics and other sensitive APIs.

Pharmaceutical formulators often face considerable challenges in maintaining the stability and bioavailability of acid-sensitive active pharmaceutical ingredients (APIs), such as peptides, proteins, and live biotherapeutics. Traditional modified-release delivery methods or specific targeting in the gastrointestinal tract often require harsh and time-consuming coating processes that can compromise the integrity of delicate molecules.

At Lonza CHI, we leverage the Capsugel® Enprotect® bi-layer capsule manufacturing technology to offer an innovative, streamlined solution for these challenges.

Key Features of Our Off-the Shelf Capsugel® Enprotect® Capsule:

• Bi-Layer Design
  • Inner Layer: Hydroxypropyl Methylcellulose (HPMC) for stability.
  • Outer Layer: HPMC acetate succinate (HPMC-AS), an enteric polymer that dissolves at pH 6.2, ensuring targeted release in the small intestine.
• No Post-Filling Processing: Ready-to-use capsules eliminate the need for additional coating or sealing, reducing the risk of API degradation.
• Robust in Harsh Conditions: Studies confirm that the capsule withstands stomach conditions and delivers the API precisely where needed in the intestine.

Beyond standard Capsugel® Enprotect® capsule: Tailored Solutions for Your Needs

• Customized Release Profiles: We can design capsules with specific release timings, whether delayed or rapid, based on your API’s therapeutic needs. This flexibility ensures highly targeted drug delivery and optimal therapeutic efficacy.

Our Capsugel® Enprotect® capsules simplify the manufacturing process, improve scalability, and offer new opportunities for oral biologics and other sensitive APIs.

For formulators looking to push the boundaries of enteric or specific delivery, our Capsugel® Enprotect® capsule and our patent-pending bi-layer manufacturing technology provides a flexible, scalable solution to meet the future needs of oral drug delivery.

Let’s talk about how we can collaborate to advance your formulations.